| name | Methocarbamol |
| classification | Muscle relaxant, centrally acting |
| pharmacokinetics | | absorption | Rapidly absorbed from the GI tract, peak plasma levels achieved within 1-2 hours. | | distribution | Distributes widely throughout the body, including the central nervous system. | | metabolism | Metabolized primarily in the liver to inactive metabolites. | | excretion | Excreted primarily in the urine as metabolites. |
|
| suggested dosage | | adult | Typically 750-1500 mg every 4-6 hours as needed, with a maximum daily dose of 4000 mg. Specific dosages may vary depending on individual patient needs and factors such as severity of symptoms and response to therapy. | | note | Dosage should be adjusted based on clinical response and tolerability. Consult a medical professional for specific dosage recommendations. |
|
| indications | | 1 | Muscle spasms associated with acute musculoskeletal conditions (e.g., low back pain, sprains, strains, myositis) | | 2 | Pain relief associated with muscle conditions | | 3 | Relief of symptoms associated with acute painful conditions such as musculoskeletal pain |
|
| safety in pregnancy | Limited data available regarding safety during pregnancy. Should be used cautiously and only when potential benefits outweigh potential risks. Consult with healthcare provider. Use is not routinely recommended during pregnancy unless the potential benefits clearly outweigh the potential risks. |
| safety in breastfeeding | Methocarbamol is excreted in breast milk. Potential risks to the nursing infant are unclear. Weigh potential benefits versus risks when considering use during breastfeeding. Consult with healthcare provider. |
| side effects | | 1 | Drowsiness | | 2 | Headache | | 3 | Nausea | | 4 | Vomiting | | 5 | Dizziness | | 6 | Dry mouth | | 7 | Constipation | | 8 | Allergic reactions (rare) | | 9 | Hypotension (rare) | | 10 | Gastrointestinal upset |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to methocarbamol or other components of the drug product. | | 2 | Severe hepatic impairment | | 3 | Severe renal impairment | | 4 | Patients with known hypersensitivity to other centrally acting muscle relaxants. | | 5 | Narrow-angle glaucoma |
|
| interactions | | 1 | Alcohol | | 2 | CNS depressants (e.g., opioids, benzodiazepines) | | 3 | Other medications that may cause drowsiness or central nervous system depression | | 4 | Drugs that may affect liver function |
|
| warnings and precautions | | 1 | May cause drowsiness. Avoid operating machinery or engaging in activities requiring alertness. | | 2 | Use with caution in patients with a history of asthma, COPD, or other respiratory conditions | | 3 | Use with caution in patients with impaired renal or hepatic function. Dosage adjustments may be necessary | | 4 | Avoid abrupt discontinuation of the drug. | | 5 | Patients with a history of drug dependence or abuse should use caution with this drug. |
|
| additional information | | 1 | Methocarbamol should be used only for the duration necessary to control symptoms and should not be used for long periods of time. | | 2 | Proper hydration is important during treatment. | | 3 | Inform the healthcare provider of all medications and supplements being taken to avoid potential drug interactions. |
|
| patient details | |
